GSK Seeks To Halt Boehringer Promos That 'Denigrate' Effectiveness Of Ellipta, Diskus Inhalers

 
• By Brenda Sandburg

US FDA's wariness of taking enforcement action against Rx drug promotions may lead to more suits like GSK's. Complaint says healthcare providers are switching COPD patients to BI's Respimat inhaler in response to BI's marketing campaign.

Young female in white t-shirt using medicine dry powder inhaler for treatment asthma/COPD diseases. Pharmaceutical product is used to treat lung inflammation and prevent asthma attack. Close up. - Image
GlaxoSmithKline seeks injunction to halt Boehringer marketing claims about its COPD inhalers

More from Marketing & Advertising

More from Compliance